Cell Death and Disease,
Journal Year:
2022,
Volume and Issue:
13(11)
Published: Nov. 4, 2022
Metastasis
is
the
dominant
cause
of
cancer-related
mortality.
Metastasis-associated
with
colon
cancer
protein
1
(MACC1)
has
been
proven
to
play
a
critical
role
in
metastasis.
However,
prometastatic
MACC1
regulating
pancreatic
(PC)
metastatic
phenotype
remains
elusive.
Here,
we
report
that
highly
expressed
The
Cancer
Genome
Atlas
(TCGA)
and
tissue
microarray
(TMA)
identified
as
good
indicator
for
poor
prognosis.
Overexpression
or
knockdown
PC
cells
correspondingly
promoted
inhibited
cell
migration
invasion
MET
proto-oncogene
receptor
tyrosine
kinase
(MET)-independent
manner.
Notably,
markedly
decreased
liver
lesions
metastasis
model.
Mechanistically,
binds
epithelial-mesenchymal
transition
(EMT)
regulator
snail
family
transcriptional
repressor
(SNAI1)
drive
EMT
via
upregulating
activity
SNAI1,
leading
transactivation
fibronectin
(FN1)
trans-repression
cadherin
(CDH1).
Collectively,
our
results
unveil
new
mechanism
by
which
drives
suggest
MACC1-SNAI1
complex-mediated
mesenchymal
may
be
therapeutic
target
cancer.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2022,
Volume and Issue:
41(1)
Published: April 23, 2022
Abstract
Background
Chemoresistance
of
pancreatic
cancer
is
the
main
reason
for
poor
treatment
effect
patients.
Exploring
chemotherapy
resistance-related
genes
has
been
a
difficult
and
hot
topic
oncology.
Numerous
studies
implicate
key
roles
circular
RNAs
(circRNAs)
in
development
cancer.
However,
regulation
circRNAs
process
ductal
adenocarcinoma
(PDAC)
resistance
not
yet
fully
clear.
Methods
Based
on
cross-analysis
Gene
Expression
Omnibus
(GEO)
database
data
our
center,
we
explored
new
molecule,
hsa_circ_0078297
(circ-MTHFD1L),
related
to
resistance.
QRT-PCR
was
used
detect
expression
circRNAs,
miRNAs,
mRNAs
human
PDAC
tissues
their
matched
normal
tissues.
The
interaction
between
circ-MTHFD1L
miR-615-3p/RPN6
signal
axis
confirmed
by
series
experiments
such
as
Dual-luciferase
reporter
assay,
fluorescence
situ
hybridization
(FISH)
RNA
immunoprecipitation
(RIP)
assays.
Results
Circ-MTHFD1L
significantly
increased
cells.
And
patients,
higher
level
circ-MTHFD1L,
worse
prognosis.
Mechanism
analysis
showed
that
an
endogenous
miR-615-3p
sponge,
upregulates
RPN6,
thereby
promoting
DNA
damage
repair
exerting
its
enhancing
gemcitabine
More
importantly,
also
found
Silencing
combined
with
olaparib
can
increase
sensitivity
gemcitabine.
Conclusion
maintains
through
axis.
may
be
molecular
marker
effective
PDAC.
Cell Reports,
Journal Year:
2023,
Volume and Issue:
42(6), P. 112581 - 112581
Published: June 1, 2023
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
a
devastating
disease
with
limited
set
of
known
driver
mutations
but
considerable
cancer
cell
heterogeneity.
Phosphoproteomics
provides
readout
aberrant
signaling
and
has
the
potential
to
identify
new
targets
guide
treatment
decisions.
Using
two-step
sequential
phosphopeptide
enrichment,
we
generate
comprehensive
phosphoproteome
proteome
nine
PDAC
lines,
encompassing
more
than
20,000
phosphosites
on
5,763
phospho-proteins,
including
316
protein
kinases.
By
using
integrative
inferred
kinase
activity
(INKA)
scoring,
multiple
(parallel)
activated
kinases
that
are
subsequently
matched
inhibitors.
Compared
high-dose
single-drug
treatments,
INKA-tailored
low-dose
3-drug
combinations
against
demonstrate
superior
efficacy
organoid
cultures,
patient-derived
xenografts.
Overall,
this
approach
particularly
effective
aggressive
mesenchymal
model
compared
epithelial
in
both
preclinical
settings
may
contribute
improved
outcomes
patients.
Oncology Reviews,
Journal Year:
2024,
Volume and Issue:
17
Published: Jan. 18, 2024
Pancreatic
cancer
is
one
of
the
most
lethal
neoplasms
worldwide;
it
aggressive
in
nature
and
has
a
poor
prognosis.
The
overall
survival
rate
for
pancreatic
low.
Most
patients
present
non-specific
symptoms
advanced
stages,
which
generally
leads
to
late
diagnosis,
at
point
there
no
option
curative
surgery.
treatment
metastatic
includes
systemic
therapy,
some
cases
radiotherapy,
more
recently,
molecular
targeted
therapies,
can
positively
impact
control
improve
quality
life.
This
review
provides
an
overview
landscape
based
on
recent
literature,
as
well
current
options
with
cancer.
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 2507 - 2528
Published: March 1, 2024
Background:
Cancer
continues
to
be
a
prominent
issue
in
the
field
of
medicine,
as
demonstrated
by
recent
studies
emphasizing
significant
role
autophagy
development
cancer.
Traditional
Chinese
Medicine
(TCM)
provides
variety
anti-tumor
agents
capable
regulating
autophagy.
However,
clinical
application
autophagy-modulating
compounds
derived
from
TCM
is
impeded
their
restricted
water
solubility
and
bioavailability.
To
overcome
this
challenge,
utilization
nanotechnology
has
been
suggested
potential
solution.
Nonetheless,
current
body
literature
on
nanoparticles
delivering
TCM-derived
for
cancer
treatment
limited,
lacking
comprehensive
summaries
detailed
descriptions.
Methods:
Up
November
2023,
research
study
was
conducted
gather
relevant
data
using
databases,
including
PubMed,
ScienceDirect,
Springer
Link,
Web
Science,
CNKI.
The
keywords
utilized
investigation
included
"autophagy",
"nanoparticles",
"traditional
medicine"
"anticancer".
Results:
This
review
analysis
overcoming
delivery
challenges
enhancing
anti-cancer
properties
TCM.
evaluation
based
synthesis
different
classes
TCM,
mechanisms
action
treatment,
benefits
reported
various
scholarly
sources.
findings
indicate
that
shows
availability
thereby
opening
up
plethora
therapeutic
avenues.
Conclusion:
Nanotechnology
enhance
efficacy
traditional
through
regulation
Keywords:
autophagy,
nano-delivery,
anti-cancer,
medicine
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Sept. 19, 2024
Abstract
Liposomal
irinotecan
has
shown
promising
antitumor
activity
in
patients
with
advanced
or
metastatic
pancreatic
ductal
adenocarcinoma
(PDAC)
who
have
undergone
prior
gemcitabine-based
therapies.
This
randomized,
double-blind,
parallel-controlled,
multicenter
phase
3
study
(NCT05074589)
assessed
the
efficacy
and
safety
of
liposomal
HR070803
combined
5-fluorouracil
(5-FU)
leucovorin
(LV)
this
patient
population.
Patients
unresectable,
locally
advanced,
PDAC
had
previously
received
therapies
were
randomized
1:1
to
receive
either
(60
mg/m
2
anhydrous
hydrochloride,
equal
56.5
free
base)
placebo,
both
combination
5-FU
(2000
)
LV
(200
),
all
given
intravenously
every
two
weeks.
The
primary
endpoint
was
overall
survival
(OS).
A
total
298
enrolled
plus
5-FU/LV
(HR070803
group,
n
=
149)
placebo
(placebo
149).
Median
OS
significantly
improved
group
compared
(7.4
months
[95%
CI
6.1–8.4]
versus
5.0
4.3–6.0];
HR
0.63
0.48–0.84];
two-sided
p
0.0019).
most
common
grade
≥
adverse
events
increased
gamma-glutamyltransferase
(19.0%
11.6%
group)
decreased
neutrophil
count
(12.9%
0
group).
No
treatment-related
deaths
occurred
while
reported
one
death
(abdominal
infection).
manageable
second-line
setting,
representing
a
potential
option
Cancers,
Journal Year:
2021,
Volume and Issue:
13(8), P. 1971 - 1971
Published: April 20, 2021
Pancreatic
ductal
adenocarcinoma
(PDAC)
represents
an
aggressive
tumor
of
the
digestive
system
with
still
low
five-year
survival
less
than
10%.
Although
there
are
improvements
for
multimodal
therapy
PDAC,
surgery
remains
effective
way
to
treat
disease.
Combined
adjuvant
and/or
neoadjuvant
treatment,
pancreatic
is
able
enhance
up
around
20%.
However,
resection
always
associated
a
high
risk
complications
and
regarded
as
one
most
complex
fields
in
abdominal
surgery.
This
review
gives
summary
on
surgical
treatment
PDAC
based
current
literature
special
focus
techniques.